146 related articles for article (PubMed ID: 11434665)
1. Somatostatin receptor scintigraphy in the follow-up of patients with differentiated thyroid cancer.
Haslinghuis LM; Krenning EP; De Herder WW; Reijs AE; Kwekkeboom DJ
J Endocrinol Invest; 2001 Jun; 24(6):415-22. PubMed ID: 11434665
[TBL] [Abstract][Full Text] [Related]
2. Thyroglobulin and low-dose iodine-131 and technetium-99m-tetrofosmin whole-body scintigraphy in differentiated thyroid carcinoma.
Gallowitsch HJ; Mikosch P; Kresnik E; Unterweger O; Gomez I; Lind P
J Nucl Med; 1998 May; 39(5):870-5. PubMed ID: 9591591
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of indium-111 pentetreotide somatostatin receptor scintigraphy to detect recurrent thyroid carcinoma in patients with negative radioiodine scintigraphy.
Valli N; Catargi B; Ronci N; Leccia F; Guyot M; Roger P; Ducassou D; Tabarin A
Thyroid; 1999 Jun; 9(6):583-9. PubMed ID: 10411121
[TBL] [Abstract][Full Text] [Related]
4. Clinical experience with recombinant human thyrotrophin (rhTSH) in the management of patients with differentiated thyroid cancer.
Mariani G; Ferdeghini M; Augeri C; Villa G; Taddei GZ; Scopinaro G; Boni G; Bodei L; Rabitti C; Molinari E; Bianchi R
Cancer Biother Radiopharm; 2000 Apr; 15(2):211-7. PubMed ID: 10803328
[TBL] [Abstract][Full Text] [Related]
5. The use of non-specific tracers in the follow up of differentiated thyroid cancer: results with Tc-99m tetrofosmin whole body scintigraphy.
Lind P; Gallowitsch HJ
Acta Med Austriaca; 1996; 23(1-2):69-75. PubMed ID: 8767519
[TBL] [Abstract][Full Text] [Related]
6. Octreotide scintigraphy in patients with differentiated thyroid carcinoma: contribution for patients with negative radioiodine scan.
Baudin E; Schlumberger M; Lumbroso J; Travagli JP; Caillou B; Parmentier C
J Clin Endocrinol Metab; 1996 Jul; 81(7):2541-4. PubMed ID: 8675574
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic management of suspected metastatic thyroid carcinoma: clinical value of octreotide scintigraphy in patients with negative high-dose radioiodine scans.
Giammarile F; Houzard C; Bournaud C; Hafdi Z; Sassolas G; Borson-Chazot F
Eur J Endocrinol; 2004 Mar; 150(3):277-83. PubMed ID: 15012611
[TBL] [Abstract][Full Text] [Related]
8. Cerebellar metastasis of papillary thyroid carcinoma detected with somatostatin receptor scintigraphy.
Czepczyński R; Wyszomirska A; Gryczyńska M; Szczepanek-Parulska E; Ruchała M
Endokrynol Pol; 2018; 69(1):24-27. PubMed ID: 29319129
[TBL] [Abstract][Full Text] [Related]
9. Does recombinant human thyrotropin-stimulated positron emission tomography with [18F]fluoro-2-deoxy-D-glucose improve detection of recurrence of well-differentiated thyroid carcinoma in patients with low serum thyroglobulin?
Vera P; Kuhn-Lansoy C; Edet-Sanson A; Hapdey S; Modzelewski R; Hitzel A; d'Anjou J; Basuyau JP
Thyroid; 2010 Jan; 20(1):15-23. PubMed ID: 20017617
[TBL] [Abstract][Full Text] [Related]
10. [Somatostatin receptor status in non-medullary thyroid carcinoma].
Görges R; Kahaly G; Müller-Brand J; Mäcke H; Walgenbach S; Bruns C; Andreas J; Brandt-Mainz K; Bockisch A
Nuklearmedizin; 1999; 38(1):15-23. PubMed ID: 9987777
[TBL] [Abstract][Full Text] [Related]
11. Thallium-201, technetium-99m-tetrofosmin and iodine-131 in detecting differentiated thyroid carcinoma metastases.
Unal S; Menda Y; Adalet I; Boztepe H; Ozbey N; Alagöl F; Cantez S
J Nucl Med; 1998 Nov; 39(11):1897-902. PubMed ID: 9829579
[TBL] [Abstract][Full Text] [Related]
12. Sensitivity of 123I whole-body scan and thyroglobulin in the detection of metastases or recurrent differentiated thyroid cancer.
de Geus-Oei LF; Oei HY; Hennemann G; Krenning EP
Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):768-74. PubMed ID: 12029550
[TBL] [Abstract][Full Text] [Related]
13. Thallium-201 scintigraphy to predict therapeutic outcome of iodine-131 therapy of metastatic thyroid carcinoma.
Nakada K; Katoh C; Kanegae K; Tsukamoto E; Shiga T; Mochizuki T; Itoh K; Tamaki N
J Nucl Med; 1998 May; 39(5):807-10. PubMed ID: 9591580
[TBL] [Abstract][Full Text] [Related]
14. Respective roles of thyroglobulin, radioiodine imaging, and positron emission tomography in the assessment of thyroid cancer.
Lind P; Kohlfürst S
Semin Nucl Med; 2006 Jul; 36(3):194-205. PubMed ID: 16762610
[TBL] [Abstract][Full Text] [Related]
15. Follow-up of differentiated thyroid cancer.
Pacini F
Eur J Nucl Med Mol Imaging; 2002 Aug; 29 Suppl 2():S492-6. PubMed ID: 12192551
[TBL] [Abstract][Full Text] [Related]
16. Comparison of thyroglobulin and radioiodine scintigraphy during follow-up of patients with differentiated thyroid carcinoma.
Johansen K; Woodhouse NJ
Eur J Med; 1992 Nov; 1(7):403-6. PubMed ID: 1341479
[TBL] [Abstract][Full Text] [Related]
17. The relevance of somatostatin receptors in thyroid neoplasia.
Ahlman H; Tisell LE; Wängberg B; Fjälling M; Forssell-Aronsson E; Kölby L; Nilsson O
Yale J Biol Med; 1997; 70(5-6):523-33. PubMed ID: 9825479
[TBL] [Abstract][Full Text] [Related]
18. Peptide receptor radionuclide therapy for non-radioiodine-avid differentiated thyroid carcinoma.
Teunissen JJ; Kwekkeboom DJ; Kooij PP; Bakker WH; Krenning EP
J Nucl Med; 2005 Jan; 46 Suppl 1():107S-14S. PubMed ID: 15653659
[TBL] [Abstract][Full Text] [Related]
19. Nuclear medicine approaches in the monitoring of thyroid cancer patients.
Sergieva S; Hadjieva T; Doldurova M; Stefanova S; Dudov A
J BUON; 2006; 11(4):511-8. PubMed ID: 17309186
[TBL] [Abstract][Full Text] [Related]
20. Influence of thyroid-stimulating hormone levels on uptake of FDG in recurrent and metastatic differentiated thyroid carcinoma.
Moog F; Linke R; Manthey N; Tiling R; Knesewitsch P; Tatsch K; Hahn K
J Nucl Med; 2000 Dec; 41(12):1989-95. PubMed ID: 11138683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]